ArticleScientific reports2025
Impact of Obesity on Perioperative and Clinical Outcomes After Robotic Assisted Radical Prostatectomy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Oncologic and perioperative outcomes following robot-assisted radical prostatectomy in morbidly obese patients: a systematic review and meta-analysis.Journal of robotic surgery · 2025Pooled it
- Perioperative and clinical outcomes in patients undergoing Retzius-sparing robot assisted radical prostatectomy stratified by the degree of obesity.International urology and nephrology · 2026Article
- Article
- Navigating the challenge: does obesity compromise outcomes in single-port robot-assisted pyeloplasty?Journal of robotic surgery · 2026Article
- Development and validation of an interpretable machine learning model for predicting urinary incontinence at 6 months after robot-assisted radical prostatectomy.Journal of robotic surgery · 2026Article
- Article
- Robot-assisted radical prostatectomy in morbidly obese men: why functional outcomes, weight-loss interventions, and anesthetic risks must complement perioperative and oncologic analysis.Journal of robotic surgery · 2025Article
- Prescription patterns demonstrate high demand for treating erectile dysfunction following radical prostatectomy.Acta oncologica (Stockholm, Sweden) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to evaluate the effect of obesity on robotic-assisted radical prostatectomy (RARP) outcomes. This study included 120 obese patients [body mass index (BMI) ≥ 30 kg/m²] and 124 normal weight (BMI ≤ 25 kg/m²)] patients from a total of 750 patients who underwent RARP between January 2017 and March 2023. The perioperative and long-term oncological and functional outcomes were also analyzed. No significant differences were observed between the groups regarding age, prostate-specific antigen (PSA) levels, or International Society of Urological Pathology (ISUP) grade distribution (p > 0.05). The obese group had significantly longer median surgical times, vesicourethral anastomosis times, hospital stays and drain removal times compared to the control group (p < 0.05). The control group demonstrated significantly better continence recovery rate at the 1st month and erectile dysfunction (ED) recovery rate at the 12th month (p < 0.05). Bilateral nerve sparing (OR: 16.59; p < 0.001) and the preoperative IIEF score (OR: 1.29; p < 0.001) were identified as independent predictors of ED recovery in the multivariable logistic regression model. Bilateral nerve sparing (OR: 3.00; p < 0.001) and the absence of metabolic syndrome (OR: 2.03; p < 0.05) were found to be independent predictors of early continence recovery. There were no differences in systemic progression or overall survival at a median follow-up of 24 months (p > 0.05). While obesity adversely impacts perioperative outcomes, short-term continence recovery rates, and mid-term ED recovery rates, it does not affect mid-term oncological outcomes after RARP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.